{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:47:53Z","timestamp":1784328473461,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/bf03161209","type":"journal-article","created":{"date-parts":[[2009,8,28]],"date-time":"2009-08-28T12:19:56Z","timestamp":1251461996000},"page":"254-257","source":"Crossref","is-referenced-by-count":58,"title":["Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP)"],"prefix":"10.1007","volume":"4","author":[{"given":"David M.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Button","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satnam","family":"Lidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul I.","family":"Dargan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF03161209_CR1","unstructured":"United Nations Office on Drugs and Crime. [webpage on the Internet]. World Drug Report 2007 [cited 2008 Aug 20]. Available from:http:\/\/www.unodc.org\/pdf\/research\/wdr07\/WDR_ 2007.pdf"},{"key":"BF03161209_CR2","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(07)60674-6","volume":"369","author":"DM Wood","year":"2007","unstructured":"Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, et al. Collapse, reported seizure\u2014and an unexpected pill.Lancet 2007; 369: 1490.","journal-title":"Lancet"},{"key":"BF03161209_CR3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09595230701255791","volume":"26","author":"J Sheridan","year":"2007","unstructured":"Sheridan J, Butler R, Wilkins C, Russell B. Legal piperazine-containing party pills\u2014a new trend in substance misuse. Drug Alcohol Rev. 2007; 26: 335\u2013343.","journal-title":"Drug Alcohol Rev."},{"key":"BF03161209_CR4","first-page":"12794","volume":"69","author":"Drug Enforcement Administration","year":"2004","unstructured":"Drug Enforcement Administration. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.Fed Regist 2004: 69; 12794\u201312797.","journal-title":"Fed Regist"},{"key":"BF03161209_CR5","unstructured":"European Monitoring Centre for Drugs and Drug Addiction [webpage on the Internet]. New Commission proposal to strengthen control of synthetic drug BZP press release [updated 2007 Jul 17; cited 2008 Aug 20]. Available from:http:\/\/europa.eu\/mpid\/pressReleasesAction.do?reference=IP\/07\/1103&format=HTML&aged=0&language=EN&guiLanguage=en"},{"key":"BF03161209_CR6","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(07)60646-1","volume":"369","author":"RF Staack","year":"2007","unstructured":"Staack RF. Piperazine designer drugs of abuse.Lancet 2007; 369: 1411\u20131413.","journal-title":"Lancet"},{"key":"BF03161209_CR7","unstructured":"Drug-Forum: The International Drugs Community discussion forum [webpage on the Internet]. TFMPP experiences [updated 2007 Dec 17; cited 2008 Aug 20]. Available from:http:\/\/www.drugs-forum.co.uk\/forum\/showthread. php?p=348422"},{"key":"BF03161209_CR8","unstructured":"Everyonedoesit.com discussion forum [webpage on the Internet]. So is it worth trying TFMPP on its own? [updated 2006 Oct 20; cited 2008 Aug 20]. Available from:http:\/\/forum.everyonedoes it.co.uk\/showthread.php?t= 76307"},{"key":"BF03161209_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drugalcdep.2004.07.014","volume":"77","author":"WE Fantegrossi","year":"2005","unstructured":"Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys.Drug Alcohol Depend 2005; 77: 161\u2013168.","journal-title":"Drug Alcohol Depend"},{"key":"BF03161209_CR10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/sj.npp.1300585","volume":"30","author":"MH Baumann","year":"2005","unstructured":"Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or \u2018Ecstasy\u2019).Neuropsychopharmacology 2005; 30: 550\u2013560.","journal-title":"Neuropsychopharmacology"},{"key":"BF03161209_CR11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pbb.2007.06.007","volume":"88","author":"HL Yarosh","year":"2007","unstructured":"Yarosh HL, Katz EB, Coop A, Fantegrossi WE. MDMA-like behavioral effects of N-substituted piperazines in the mouse.Pharmacol Biochem Behav 2007; 88: 18\u201327.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF03161209_CR12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0091-3057(92)90403-3","volume":"43","author":"JL Herndon","year":"1992","unstructured":"Herndon JL, Pierson ME, Glennon RA. Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine.Pharmacol Biochem Behav 1992; 43: 739\u2013748.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF03161209_CR13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0091-3057(88)90390-5","volume":"31","author":"MD Schechter","year":"1988","unstructured":"Schechter MD. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d).Pharmacol Biochem Behav 1988; 31: 817\u2013824.","journal-title":"Pharmacol Biochem Behav"},{"key":"BF03161209_CR14","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/BF00558281","volume":"6","author":"H Campbell","year":"1973","unstructured":"Campbell H, Cline W, Evans M, Lloyd J, Peck A. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts.Eur J Clin Pharmacol 1973; 6: 170\u2013176.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF03161209_CR15","first-page":"U1784","volume":"118","author":"P Gee","year":"2005","unstructured":"Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP based herbal party pills in humans: a prospective study in Christchurch, New Zealand.N Z Med J 2005; 118: U1784.","journal-title":"N Z Med J"},{"key":"BF03161209_CR16","unstructured":"The Vaults of Erowid [webpage on the Internet]. TFMPP legal status. [updated 2008 Apr 01; cited 2008 Aug 20]. Available from:http:\/\/www.erowid.org\/chemicals\/tfmpp\/tfmpp_law.shtml"},{"key":"BF03161209_CR17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00228-007-0451-9","volume":"64","author":"PI Dargan","year":"2008","unstructured":"Dargan PI, Button J, Hawkins L, Archer J, Ovaska H, Lidder S, et al. Detection of the pharmaceutical agent \u2018Glaucine\u2019 as a recreational drug.Eur J Clin Pharmacol 2008; 64: 553\u2013554.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF03161209_CR18","doi-asserted-by":"crossref","unstructured":"Ovaska H, Viljoen A, Puchnarewicz M, Button J, Ramsey J, Holt DW, et al. First case report of recreational use of 2, 5-dimethoxy-4-chloroamphetamine (DOC) confirmed by toxicological screening.Eur J Emerg Med 2008; in press.","DOI":"10.1097\/MEJ.0b013e3282fc765b"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03161209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03161209\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03161209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T02:36:29Z","timestamp":1558492589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03161209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["BF03161209"],"URL":"https:\/\/doi.org\/10.1007\/bf03161209","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}